KaloBios tacks on $12M more for engineered antibodies
South San Francisco, Calif.-based KaloBios, a biotech company that raised $20 million just five months ago, has added another $12 million in a second close of its fourth round of venture capital.
KaloBios has three antibody products in development, each of which targets a specific set of diseases. Two of the candidates, KB001 and KB002, have made it to Phase 2 clinical testing.
The new funding was led by Baxter International, one of the world’s largest healthcare… Continue Reading
Engineered antibody maker KaloBios takes on $20M for clinical trials
South San Francisco, Calif.-based KaloBios Pharmaceuticals, which develops non-human antibodies for use in human bodies, has taken $20 million in its fourth round of venture funding.
KaloBios is currently going through seven first- and second-phase clinical trials for two drugs and is working on a third, newer drug. The drugs are aimed at patients with cystic fibrosis and autoimmune disorders like asthma.
Mitsubishi UFJ Capital and Genzyme Ventures co-led the round. Also participating were previous investors MPM… Continue Reading